Back to Search Start Over

Real-World Evidence of Dydrogesterone 20 mg and 30 mg SR Usage in Pregnancy.

Authors :
Manickavasagam M
Vakil A
Singh E
Roy H
Lal N
Patel RG
Mishra R
Gudibanda S
Shah S
Source :
Cureus [Cureus] 2024 Oct 21; Vol. 16 (10), pp. e72016. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background Dydrogesterone, an oral selective progesterone receptor agonist with high bioavailability, has been used since the 1960s to treat various conditions arising due to the deficiency of progesterone. Patients are expected to have additional compliance and reduced pill burden with dydrogesterone 20 mg and 30 mg SR once a day (OD) for conditions requiring 10 mg twice a day (BID) or thrice a day (TID). Methodology A real-world analysis was conducted using the HealthPlix electronic medical records (EMR) database to understand the demography, indications, and prescription patterns of dydrogesterone 20 mg and 30 mg SR, including co-prescriptions. Results The mean age of the female patients prescribed dydrogesterone 20 mg SR was 27.23 ± 4.79 years while those prescribed 30 mg SR had a mean age of 28.56 ± 5.17 years. Common indications for the prescription of dydrogesterone 20 mg SR were pregnancy, infertility, and abortion/miscarriage. Pregnancy, infertility, and amenorrhea were the common conditions for dydrogesterone 30 mg SR prescription. The average duration of prescription of dydrogesterone 20 mg and 30 mg SR was 55.50 ± 31.33 and 79.66 ± 68.38 days, respectively. OD regimen was the preferred regimen for dydrogesterone 20 mg SR (89.48%) and dydrogesterone 30 mg SR (64.06%). Conclusions This analysis suggests dydrogesterone 20 mg and 30 mg SR are being prescribed for various indications in the real world with significant variation in the prescription patterns.<br />Competing Interests: Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Royal Pune Independent Ethics Committee issued approval RPIEC140824. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.<br /> (Copyright © 2024, Manickavasagam et al.)

Details

Language :
English
ISSN :
2168-8184
Volume :
16
Issue :
10
Database :
MEDLINE
Journal :
Cureus
Publication Type :
Academic Journal
Accession number :
39569237
Full Text :
https://doi.org/10.7759/cureus.72016